The multimillion-dollar acquisition in London of the Wellcome Foundati
on by Glaxo promises, on one hand, to cost many scientists their jobs,
but, on the other, to boost the coffers of a research foundation supp
orted by the sale of Wellcome shares. For U.S. scientists, the news on
both fronts is bad.